The Lancet Infectious Diseases Publishes Results from Paratek’s Phase 3 Oral only Dosing Study of NUZYRA® (omadacycline) for Skin Infections

Once-daily NUZYRA is non-inferior to twice-daily oral linezolid for the treatment of adults with ABSSSI, including MRSA; confirms efficacy and safety of oral-only formulation